Samsung Biologics Co.,Ltd.
Research Samsung Biologics Co.,Ltd. (207940) on Bullrun: market cap KRW 64.95T. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker207940
- ExchangeKS
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 64.95T
- Financial periodQ2 2026
- RevenueKRW 1.32T
- Net incomeKRW 430.65B
- Free cash flowKRW 525.72B
- Gross margin53.0%
Valuation Snapshot
latest market cap is KRW 64.95T.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | KRW 4.26T | KRW 1.78T | KRW 772.73B | 54.6% | n/a | KRW 148.85B | KRW 927.09B | KRW 7.45T |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-16 | KRW 64.95T | n/a | n/a | n/a |
About Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services;
ETFs that hold Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd. is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| Invesco MSCI Emerging Markets ESG Climate Paris Aligned UCITS ETF USD Acc | 1.68% | 0.19% |
Compare every fund on the same index:
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Samsung Biologics Co.,Ltd.'s market cap?
Samsung Biologics Co.,Ltd.'s market capitalization is KRW 64.95T.
What does Samsung Biologics Co.,Ltd. do?
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing.